Showing 1 - 7 of 7
pharmaceuticals, specifically drug reformulation regulatory gaming. …
Persistent link: https://www.econbiz.de/10009205060
pharmaceuticals. We challenge this orthodox view and show, to the contrary, that the pace of innovation often is faster in a world …
Persistent link: https://www.econbiz.de/10005666872
This paper addresses the relationship between patent protection and investment in the development of new pharmaceutical treatments. The TRIPS Agreement, which specifies minimum levels of intellectual property protection for countries in the World Trade Organization, has increased levels of...
Persistent link: https://www.econbiz.de/10009002387
the hypothesis that innovation in pharmaceuticals is becoming more difficult and expensive over time, as costs of …
Persistent link: https://www.econbiz.de/10009003149
creating an internal market for pharmaceuticals can be analysed. In a model of third-degree price discrimination, arbitrage … Market in pharmaceuticals are ambiguous, since a movement from segmented and price-controlled markets towards integrated …
Persistent link: https://www.econbiz.de/10005114350
Preventives are sold ex ante, before disease status is realized, while treatments are sold ex post. Even if the mean of the ex ante distribution of consumer values is the same as that ex post, the shape of the distributions may differ, generating a difference between the surplus each product can...
Persistent link: https://www.econbiz.de/10011196028
We provide a method allowing to identify margins in an oligopoly price competition game when prices may not be freely chosen in some markets, for example due to regulation. We use our identification strategy to study the effects of regulatory constraints in the pharmaceutical industry, which is...
Persistent link: https://www.econbiz.de/10011083879